Sunitinib treatment in patients with severe renal function impairment: A report of four cases by the hellenic cooperative oncology group

Clinical Nephrology

Volumn 72, Issue 1, 2009, Pages 73-78

  Lainakis, G ^a   Bamias, A ^a,c   Psimenou, E ^a   Fountzilas, G ^b   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c NONE   (Greece)

Author keywords

Renal cell carcinoma; Renal impairment; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

CREATININE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; NEBIVOLOL; RAMIPRIL; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE REGULATION; BONE MARROW TOXICITY; BONE METASTASIS; CANCER GRADING; CASE REPORT; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; SKIN DISCOLORATION; THROMBOCYTOPENIA; KIDNEY TUMOR; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; NEPHRECTOMY; PYRROLES;

EID: 70349233039     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72073     Document Type: Article

References (23)

1. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI. Toxicities associated with the administration of Sorafenib, Sunitinib, and Temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008; 53: 917-930.
2. Chow LQM, Eckhardt SG. Sunitinib: From rational design to clinical efficacy J Clin Oncol. 2007; 25: 884-896.
3. Cockroft DW, Gault MH. Prediction ofCreatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
4. Cohen H, McGovern F. Renal cell carcinoma. N Engl J Med. 2005; 353: 3477-3490.
5. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005:CD001425.
6. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes. J Am Soc Nephrol. 2001; 12: 993-1000.
7. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358: 1129-1136.
8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek, Melichar B, Bajetta E, Gorbunova V, Bay J.O, Bodrogi I, Jagiello-Gruszfeld A, Moore N. Bevacizumab plus interferon alfa-2a for the treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 22-29.
9. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, DePrimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24: 25-35.
10. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Négrier S, Huang X, Kim ST, Chen I, Motzer RJ. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment for metastatic renal cell carcinoma (mRCC). Oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology. 2008; abstract 5024.
11. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002; 29: 41-46.
12. Goresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Study. Am J Kidney Dis. 2003; 41: 1-12.
13. Houk BE, Amantea M, Motzer RJ, Michaelson MD, Rini BI, George DG, Redman BG, Hudes GR, Poland B. Bello CL. Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006; 24(Suppl 18): 4531 (Abstract).
14. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007; 18: 1745-1747.
15. Khosravan R, Toh M, LaFargue J, Ni G, Bello C. Sunitinib pharmacokinetic and safety data in subjects with renal impairment and on hemodialysis. Poster presentation at the 44th Annual Meeting of the American Society of Clinical Oncology. 2008; Abstract 2578.
16. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007; 110: 1376-1384.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson M.D, Bukowski R.M, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
18. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24.
19. Pfizer Inc. Sutent® (sunitinib malate) prescribing information. Pfizer Inc.; May 2008.
20. Pfizer Labs. Sutent® (sunitinib malate) capsules. 2006a; Available online at: www.fda.gov/cder/foi/label/2006/021968lbl.pdf.
21. Pfizer Labs. US Product Monograph: Sunitinib. 2006b; Available online at: www.pbm.va.gov/monograph/Sunitinib.pdf.
22. Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang Y, Chidambaram N, Jiang J.X, Tang S, Mahjoob K, Justice R, Pazdur R. Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma. Clin Can Res. 2007; 13: 1367-1373.
23. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004; 65: 2003-2017.